Diabetes in India — A Clear, Compassionate Summary

Quick facts (what the evidence says)

• How common? As many as ~15–18% or more have diabetes and the rates are increasing at an alarming rate.
• Diagnosed vs undiagnosed: Roughly 40–53% of people with diabetes remain undiagnosed in India.
• At presentation — around 40–45% have hypertension and 80% of patients have dyslipidemia (especially high triglycerides and low HDL).
• Obesity patterns: Approximately 50% have obesity at presentation; but importantly many Indians have 'normal-weight obesity' and national studies show a large proportion of adults are metabolically unhealthy even if not overtly obese.
• Visceral fat matters: Indians develop visceral fat and insulin resistance at lower BMIs — this drives early heart disease, fatty liver (MAFLD), and kidney disease. CVD in Indians often appears 1–2 decades earlier than in many Western groups.

What happens over time — heart & kidney disease

• Heart disease: People with diabetes have 2–4× higher risk of coronary artery disease. And as many as 80–90% of Indians develop some sort of heart disease. Even with the best treatment as many as 37% have silent sub-clinical heart failure despite a normal pumping heart. Among Indians, coronary artery disease (heart attacks) tends to occur at younger ages; population data show substantial CVD prevalence.
• Kidney disease: Diabetic kidney disease (DKD) — recent multicentre data show DKD can be present in about a third of clinic populations.

Life expectancy and the power of good care

• Life years lost: International analyses show diabetes shortens life expectancy — on an average anywhere between 4–10 years of life lost, and as much as 15–17 years if they have any evidence of diabetic kidney disease (leaking protein from the kidney), with younger age at diagnosis costing more years. (At age 50, many studies report ~6 years shorter life expectancy in people with T2D vs without.)

Why diabetes in India is “different”

1. Genetics + early life nutrition → Indians store fat centrally and develop insulin resistance at lower BMI.
2. High visceral and ectopic fat (epicardial, hepatic) even with modest BMI → earlier heart, liver and kidney disease.
3. Rapid urbanisation & lifestyle shifts (physical inactivity, processed food, sedentary jobs) have increased risk across ages.
4. Late diagnosis & poor follow-up in many places → people present with complications already established.

Practical risk assessment

• Age > 50 years and diabetes duration > 7 years = substantially higher risk of heart & kidney complications.
• Other high-risk features: poor glucose control (high HbA1c), high blood pressure, high triglycerides, albuminuria (leaking kidneys), reduced kidney function as assessed by eGFR, smoking, family history of premature CVD, raised inflammatory marker (hs-CRP).
• Tests to know: fasting blood sugar/HbA1c, blood pressure, lipid profile (including triglycerides), urine albumin (microalbumin/albumin-creatinine ratio), eGFR, liver function tests, ECG and echocardiography on a regular basis even for those without any symptoms.

Ten succinct, compassionate take-home points for patients

1. 1 in 9 Indian adults has diabetes, with urban rates being higher.
2. Nearly half are undiagnosed — early testing saves lives.
3. Diabetes often comes with high blood pressure, high triglycerides and fatty liver — check them at diagnosis.
4. Normal BMI does not guarantee safety — hidden visceral fat (“normal-weight obesity”) raises cardio-renal risk.
5. Heart and kidney disease happen earlier in Indian diabetics — early screening is essential.
6. As many as 30–40% with diabetes will develop diabetic kidney disease over time (clinic estimates vary); and up to 90% will develop heart disease. Regular checks = early treatment.
7. Losing weight, lowering HbA1c, controlling BP and lipids markedly reduces complications — even small gains matter.
8. If you are over 50 or have had diabetes > 7 years, your risk is higher — ask for heart and kidney tests even if you feel fine.
9. With good care and regular follow-up, many years of life and quality of life can be preserved — diabetes is manageable, not inevitable decline.
10. Seek a team approach: doctor + dietitian + exercise + family support — diabetes is a long-term condition that needs kind, steady care.

Our research in this area

Peer-reviewed publications and conference presentations by Dr. Vishal Gupta and colleagues.

1. Gupta V, et al. An observational study to evaluate change in dose requirement of standard glucose-lowering, lipid-lowering, and antihypertensive therapy treated with SGLT2 inhibitor (canagliflozin) over one year, in fifty T2DM patients. Diabetes 2018;67(Suppl_1):1165–P. doi:10.2337/db18-1165-P
2. Gupta V, Willis M, Johansen P, Nilsson A, Shah M, Mane A, Neslusan C. Long-term clinical benefits of canagliflozin 100 mg versus sulfonylurea in patients with type 2 diabetes mellitus inadequately controlled with metformin in India. Value Health Reg Issues 2019 May;18:65–73. PMID:30502662. doi:10.1016/j.vhri.2018.06.002
3. Gupta V, Canovatchel W, Lokesh BN, Santani R, Garodia N. Sodium-glucose cotransporter-2 inhibitors: moving beyond the glycemic treatment goal. Indian J Endocrinol Metab 2017;21(6):909–918. PMID:29285458. doi:10.4103/ijem.IJEM_85_17
4. Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or NPH to biphasic insulin aspart 30 in people with type 2 diabetes. J Med Econ 2015;18(4):263–272. PMID:25426701. doi:10.3111/13696998.2014.991791
5. Gupta V, et al. Predictive and explanatory factors of change in health-related quality of life after starting insulin analogs. ADA abstract, June 2015.
6. Shafie AA, Gupta V, Baabbad R, Hammerby E, Home P. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2014;106(2):319–327. PMID:25305133. doi:10.1016/j.diabres.2014.08.024
7. Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab 2013;17(3):413–421. PMID:23869296. PMCID:PMC3712370. doi:10.4103/2230-8210.111625
8. Talwalkar PG, Gupta V, Kovil R. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: results from the Mumbai cohort of the A1chieve study. Indian J Endocrinol Metab 2013;17(Suppl 2):S516–S520. PMID:24404494. PMCID:PMC3872902. doi:10.4103/2230-8210.122107
9. Kalra S, Gupta V. The diversity of diabetes. In: Bajaj S, ed. ESI Manual of Clinical Endocrinology. Hyderabad: Endocrine Society of India; 2012. p.3–5.
10. Gupta V. Pleiotropic effects of incretins. Indian J Endocrinol Metab 2012;16(Suppl 1):S47–S56. PMID:22701844. PMCID:PMC3354942. doi:10.4103/2230-8210.94259
11. Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab 2011;15(4):298–308. PMID:22029001. PMCID:PMC3193779. doi:10.4103/2230-8210.85583